Показать сокращенную информацию
dc.contributor.author | Shanazarov N.A. | |
dc.contributor.author | Benberin V.V. | |
dc.contributor.author | Seidalin N.K. | |
dc.contributor.author | Khalirakhmanov A.F. | |
dc.contributor.author | Gaziyev E.A. | |
dc.contributor.author | Zinchenko S.V. | |
dc.date.accessioned | 2021-02-25T20:36:18Z | |
dc.date.available | 2021-02-25T20:36:18Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 0975-8453 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/162000 | |
dc.description.abstract | © 2020 EManuscript Technologies. All rights reserved. The use of modern chemotherapeutic drugs in the treatment of cancer is asso-ciated with various side effects. Cardiovascular complications include various heart rhythm disorders, heart failure, arterial and venous thrombosis of vari-ous localizations. This review article describes the pathophysiological features of various groups of chemotherapeutic drugs that are actively used in everyday practice, which lead to the occurrence of acute coronary syndrome. It also de-scribes the features of percutaneous coronary interventions in patients under-going chemotherapy. | |
dc.relation.ispartofseries | Systematic Reviews in Pharmacy | |
dc.subject | Acute coronary syndrome | |
dc.subject | Cardioncology | |
dc.subject | Chemotherapy | |
dc.subject | Metabolic syndrome | |
dc.subject | Percutaneous coronary interventions | |
dc.title | Acute coronary syndrome during chemotherapy | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 11 | |
dc.relation.ispartofseries-volume | 11 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 1135 | |
dc.source.id | SCOPUS09758453-2020-11-11-SID85097628355 |